Leukemia: Family history of plasma cell disease is associated with increased survival rates for MGUS, multiple myeloma, and systemic AL amyloidosis

The relationship between familial plasma cell disease (PCD) and monoclonal antibody disease (MGUS), multiple myeloma (MM), and systemic light chain (AL) amyloidosis has not been well described

The relationship between familial plasma cell disease (PCD) and monoclonal antibody disease (MGUS), multiple myeloma (MM), and systemic light chain (AL) amyloidosis has not been well described

Therefore, a foreign research team retrospectively reviewed the results of 25,423 patients (16,744 MGUS, 6194 MM, 2955 AL amyloidosis)

Therefore, a foreign research team retrospectively reviewed the results of 25,423 patients (16,744 MGUS, 6194 MM, 2955 AL amyloidosis)

Familial association of a proband who reports a family history of PCD

The overall survival of patients with a family history of PCD and those without a family history of PCD

The overall survival of patients with a family history of PCD and those without a family history of PCD The overall survival of patients with a family history of PCD and those without a family history of PCD Expect

Overall, 2.

Overall, 2.

The cumulative incidence of MGUS progression to MM, a lymphoproliferative disease, or systemic AL amyloidosis, and death as a competitive risk MGUS progression to MM, a lymphoproliferative disease, or the accumulation of systemic AL amyloidosis Incidence rate, using death as a competitive risk

Although studies have shown that family history of PCD may increase the risk of disease progression, there is currently no data showing that MGUS screening can improve health outcomes

Although studies have shown that family history of PCD may increase the risk of disease progression, there is currently no data showing that MGUS screening can improve health outcomes

Original source:

Original source:

Visram, A.

Visram, A.

Leave a message here